IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems.
Toll-like receptor (TLR) agonists have a proven potential to become the adjuvants of the next generation when admixed and formulated with all kinds of vaccine compositions. The quality and magnitude of a vaccine-induced immune response is often strongly facilitated by TLR agonists, with the result that protection is increased and expanded toward type 1-driven immunity. DNA oligodeoxynucleotides bind to TLR9 and have been tested in a variety of vaccine settings with encouraging results. Combining oligodeoxynucleotides with poly-L-arginine (IC30) or certain artificial antimicrobial peptides dramatically improves and synergizes with the adjuvant action of TLR9 agonists, a notion that has prompted the development of IC31, an adjuvant with a promising profile in both preclinical and clinical trials.
Lingnau
Karen
K
Intercell AG, Campus Vienna Biocenter 6, 1030 Vienna, Austria. klingnau@intercell.com
Riedl
Karin
K
von Gabain
Alexander
A
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D006801:Humans; D022223:Vaccines, Subunit / Q000008:administration & dosage* / Q000276:immunology
D000276:Adjuvants, Immunologic; D022223:Vaccines, Subunit